Genetically modified mice are extremely valuable tools for studying gene function and human diseases. Although the generation of mice with specific genetic modifications through traditional methods using homologous recombination in embryonic stem cells has been invaluable in the last two decades, it is an extremely costly, time-consuming, and, in some cases, uncertain technology. The recently described CRISPR-Cas9 genome-editing technology significantly reduces the time and the cost that are required to generate genetically engineered mice, allowing scientists to test more precise and bold hypotheses in vivo. Using this revolutionary methodology we have generated more than 100 novel genetically engineered mouse strains. In the current protocol, we describe in detail the optimal conditions to generate mice carrying point mutations, chromosomal deletions, conditional alleles, fusion tags, or endogenous reporters.
DNeasy Blood & Tissue Kit (QIAGEN 69581) EDTA (0.5 M, pH 8.0) (AmericanBio AB00502-01000) EndoFree Plasmid Maxi Kit (QIAGEN) Gene-specific primers for genotyping (Sigma-Aldrich) Human chorionic gonadotropin (hCG; Sigma-Aldrich C8554) Hyaluronidase (from bovine testes) (Sigma-Aldrich H4272) M2 medium (Sigma-Aldrich M7167) M16 medium (Sigma-Aldrich M7292) MEGAclear Transcription Clean-Up Kit (Life Technologies AM1908) MEGAshortscript T7 Transcription Kit (Life Technologies AM1354) Mice, C57BL/6, age 3-4 wk (female) and >8 wk (male) (The Jackson Laboratory)
These mice are used to produce zygotes.
Mice, ICR (Institute for Cancer Research) (CD-1) mice (males and females) (Charles Rivers Laboratories)
These are used for pseudopregnant foster mothers and vasectomized males. Pregnant mare serum gonadotropin (PMSG; Sigma-Aldrich G4527) QIAquick PCR Purification Kit (QIAGEN 28106) Single-strand DNA (ssDNA) (Integrated DNA Technologies) (see Step 2) These oligo DNAs are used to insert small DNA fragments and should be ordered as a 4-nm ultramer, desalted. Include phosphorothioate linkages to prevent degradation in the first and last three nucleotides of the oligo DNAs. 
METHOD
Single Guide RNA (sgRNA) Design 1. For sgRNA design, follow the protocol described by Ran et al. (2013) .
The type of sgRNA required will depend on the specific type of genetic alteration desired.
• For gene knockouts by indels, design the sgRNA for the targeted gene. For multiple-gene knockouts by indels in a single embryo, design two or more sgRNAs to target each gene.
• For targeted chromosomal deletions, design two sgRNAs, each of which will generate a double-strand break (DSB) at the start and end point of the sequence to be deleted.
• To introduce a small DNA sequence (e.g., point mutation, fusion tag), design a single sgRNA.
• To generate a conditional allele by inserting two loxPs in cis, design two sgRNAs at the insertion sites of interest.
• To introduce a large DNA sequence (e.g., a fluorescent protein) by homologous recombination (HR), design a single sgRNA at the insertion site of interest.
Donor Design
2. Design donor DNA depending on the specific type of genetic alteration desired.
• To introduce a short DNA sequence (e.g., point mutation, fusion tag), design a singlestranded DNA (ssDNA) oligonucleotide that encodes the desired DNA insertion flanked on each side by 50-70 bases homologous to the sequence surrounding the sgRNA-mediated DSB. Insert the sequence as close as possible to the generated DSB.
We have been able to introduce up to 100 bases with homologous regions of 50 bases on each side.
• To generate a conditional allele by introducing two loxP sites, design two ssDNA oligonucleotides that encode the loxP sequence flanked on each side by 63 bases homologous to the sequence surrounding the sgRNA-mediated DSB. Insert the loxP sequence as close as possible to the generated DSB.
• To introduce a large DNA sequence (e.g., a fluorescent protein), design and construct a plasmid that encodes the DNA sequence to be inserted flanked by >2 kb of homology on
Cite this protocol as Cold Spring Harb Protoc; doi:10.1101/pdb.prot090704 each side using standard molecular biology methods. Insert the DNA sequence of interest as close as possible to the generated DSB.
We have been able to introduce large fragments of DNA with smaller homology regions (~500 bp).
When introducing a small or a large DNA fragment, a potential problem should be considered. After induction of the DSB and the DNA sequence has been inserted in the genome by homology-directed repair (HDR) or HR, it is possible that the Cas9 endonuclease can recut the modified allele if the sgRNA and protospacer-adjacent motif (PAM) sequence have not been modified in the donor ssDNA or circular DNA vector. To prevent this, place the DNA sequence that encodes the desired insertion in a position in which the PAM sequence or the six nucleotides closest to the PAM sequence are disrupted (Fig. 1C) .
In Vitro Transcription and Purification of Cas9 mRNA 3. Linearize the pMJ920-Cas9 plasmid containing the Cas9 endonuclease coding region under the T7 promoter with XbaI by incubating the following reaction for 16 h at 37˚C.
Reagent Volume
Circular pMJ920-Cas9 plasmid 5 µL (5 µg of plasmid total) XbaI restriction enzyme 0.5 µL CutSmart buffer (10×) 5 µL Nuclease-free water 39.5 µL 4. Add 1.5 µL of proteinase K (150 ng/µL) and 2.5 µL 20% SDS to the reaction mix. Incubate for 30 min at 50˚C. 5. Analyze 5 µL of the digestion reaction on a 1% (w/v) agarose gel in TAE buffer to verify the successful linearization of the pMJ920-Cas9 plasmid. 6. Purify the linearized pMJ920-Cas9 plasmid with phenol:chloroform:isoamyl alcohol (25:24:1) according to the manufacturer's instructions. Resuspend the purified linearized pMJ920-Cas9 plasmid to a concentration of 1 µg/µL using nuclease-free water. 7. Use 1 µg of the purified linearized pMJ920-Cas9 plasmid as the template for in vitro transcription to generate Cas9 mRNA using the mMESSAGE mMACHINE T7 Ultra Transcription Kit according to the manufacturer's instructions. 8. Purify the Cas9 mRNA using the MEGAclear Transcription Clean-Up Kit according to the manufacturer's instructions, and elute it with 65 µL of elution buffer. Insertion of EcoRI (as an example; blue) adjacent to the PAM sequence (red) will preclude the Cas9 endonuclease from cutting again after the genome has been repaired by HDR.
9. After purification, determine the quality of the Cas9 mRNA by analyzing 2.5 µL of the Cas9 mRNA pre-and postpolyadenylation in a Bioanalyzer using the Agilent RNA 6000 Pico reagents and chips according to the manufacturer's instructions.
A discrete~4-kb band should be observable in the sample prepolyadenylation, with an upward shift postpolyadenylation (Fig. 1A) . Smeared bands indicate degradation. Discard degraded samples.
10. Calculate the concentration of the Cas9 mRNA according to the values reported in the Bioanalyzer (Fig. 1B) . 11. Dilute the Cas9 mRNA to 400 ng/µL in nuclease-free microinjection buffer (5 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, pH 8.0). Freeze aliquots at −80˚C.
In Vitro Transcription and Purification of sgRNAs 12. For sgRNA preparation, add the T7 promoter sequence to the sgRNA template(s) (from Step 1, as appropriate) by PCR amplification using the T7-sgRNA_F and sgRNA_R primers as follows. 14. Analyze 5 µL of the PCR on a 2.5% (w/v) agarose gel in 1× TAE buffer to verify that the product is unique and of the expected size.
The size of the PCR product is~120 bp for sgRNA templates.
15. Purify the T7-sgRNA PCR product using the QIAquick PCR purification kit according to the manufacturer's instructions. 16. Elute in 30 µL of nuclease-free water and resuspend the purified PCR product to a concentration of 120.5 ng/µL. 17. Use 1 µL of the purified T7-sgRNA PCR product as the template for in vitro transcription of sgRNA using the MEGAshortscript T7 Transcription Kit according to the manufacturer's instructions. 18. Purify the sgRNA using the MEGAclear Transcription Clean-Up Kit and elute with elution buffer according to the manufacturer's instructions. 19. Dilute the sgRNA to 500 ng/µL in nuclease-free microinjection buffer (5 mM Tris-HCl, pH 7.4, 0.1 mM EDTA, pH 8.0). 20. Verify the sgRNA's quality on a 2% (w/v) agarose gel in TAE buffer. 
Preparation of Samples for Microinjection
27. Centrifuge thawed stock aliquots of the Cas9 mRNA (from Step 11), sgRNAs (from Step 21), and/or ssDNA donor oligos (from Step 24) at 13,200 rpm for 10 min at 4˚C. 28. Depending on the aim of the experiment, prepare the appropriate injection mix by combining the components in an RNase-free microcentrifuge tube as described below.
• For gene disruption by nonhomologous end joining or small/large chromosomal deletions add 10 µL of Cas9 mRNA stock (from Step 11), 4 µL of each sgRNA stock (from Step 21), and nuclease-free microinjection buffer up to 40 µL.
The final concentrations are 100 ng/µL of Cas9 mRNA and 50-100 ng/µL of each sgRNA.
• For point mutations, small tag insertions or conditional allele generation by HDR add 10 µL of Cas9 mRNA stock (from Step 11), 4 µL of each sgRNA stock (from Step 21), 8 µL of donor ssDNA stock (from Step 24), and nuclease-free microinjection buffer up to 40 µL.
The final concentrations are 100 ng/µL of Cas9 mRNA, 50-100 ng/µL of each sgRNA, and 100 ng/µL of each donor ssDNA.
• For large fragment insertion by HR add 10 µL of Cas9 mRNA stock (from Step 11), 4 µL of each sgRNA stock (from Step 21), the circular DNA donor vector (from Step 26), and nuclease-free microinjection buffer up to 40 µL.
The final concentrations are 100 ng/µL of Cas9 mRNA, 50-100 ng/µL of each sgRNA, and 200 ng/µL of the circular DNA donor vector.
29.
Centrifuge the microinjection mixture at 13,200 rpm for 6 min at 4˚C. Remove 30 µL and transfer to a new RNase-free microcentrifuge tube. 30. Centrifuge the microinjection mixture at 13,200 rpm for 6 min at 4˚C. Place the mixture on ice and begin microinjection.
Zygote Preparation
31. Inject 15 female C57BL/6-(3-to 4-wk-old) mice with PMSG (5 IU) on day 1.
32.
After 48 h (i.e., on day 3), inject female mice with hCG (5 IU). After the hCG injection, house female mice with C57BL/6 male mice of proven fertility overnight. 33. On the morning of day 4, collect female mice with cervical plugs for zygote preparation. Euthanize the female mice without plugs.
34.
Prepare the medium for embryo culture. i. Place several drops (30-50 µL per drop) of M16 medium on a 60-mm dish.
ii. Cover the drops with light mineral oil.
iii. Place the dish into a 37˚C incubator for at least 30 min before use.
35. At 20-21 h after hCG injection, kill the mice and collect zygote-cumulus complexes from the oviduct. 36. Prepare the medium for embryo collection by adding hyaluronidase to M2 media to obtain a working concentration of 300 µg/mL (M2 + Hy medium). 37. Move the zygote-cumulus complexes into M2 + Hy medium in a 100-mm dish. Pipette up and down several times. Aspirate the embryos with a transfer pipette. 38. Wash several times in M2 medium.
39. Place the embryos into M16 medium at 37˚C in a 5% CO 2 incubator until ready for microinjection.
Microinjection of Zygotes

40.
Use a transfer pipette to transfer a group of fertilized oocytes into the injection chamber containing M16 medium. Wait for at least 5 min before starting the injection.
The number of zygotes to be moved into the microinjection drop should be determined by the skills of the injector and quality of the setup.
41. Examine the zygotes under high power, making sure that two pronuclei are visible and that the morphology is good. Discard all zygotes that appear abnormal. 42. Aspirate the injection mix into microinjection capillary. 44. To prepare a zygote for injection, place the tip of the holding pipette next to the zygote, and apply a negative pressure to the pressure control unit. 45. Focus the microscope to locate the pronuclei.
The pronucleus should also be as close as possible to the central axis of the holding pipette.
46. Refocus on the pronucleus to be injected. Bring the tip of the microinjection capillary into the same focal plane as the mid-plane of the pronucleus. 47. Move the injection pipette to the same y-axis position as the targeted pronucleus.
48. Adjust the height of the pipette so that the tip of the microinjection capillary appears completely sharp. 49. Move the injection pipette to a 3 o'clock position without changing its height.
50. Push the microinjection pipette through the zona pellucida into the cytoplasm and toward the pronucleus. 51. When the tip of the microinjection capillary appears to be inside the cytoplasm apply injection pressure through the injector.
52.
Quickly pull the pipette out of the zygote.
Repeat Steps 44-52 with the remaining zygotes.
Some injected zygotes will inevitably lyse because of the mechanical damage caused by the injection procedure. The lysed zygotes can be distinguished from healthy ones by the appearance of the zona pellucida as it is more translucid. Typically,~75% of the zygotes survive the microinjection.
54. After all the zygotes in the chamber have been injected immediately transfer them back into M16 medium and incubate at 37˚C in a 5% CO 2 incubator.
Embryo Transfer and Production of Mice
55. Prepare pseudopregnant foster mothers by mating estrous CD1 female mice with vasectomized male mice on the same day as injection. 56. Transfer approximately 25 microinjected zygotes into oviducts of 0.5 d postcoitum (dpc) recipients.
Alternatively, injected zygotes can be cultured in M16 medium at 37˚C in a 5% CO 2 incubator until they reach the two-cell stage 24 h later and then be transferred into oviducts of 0.5 d postcoitum (dpc) recipients.
57. Deliver pups from recipient mothers at 19.5 dpc.
58. Separate male and female offspring into individual cages at 3 wk after birth.
Genotyping 59. Extract genomic DNA from tail biopsies of 10-d-old mice using a DNeasy blood and tissue kit according to the manufacturer's protocol. • To check for indels or small mutations perform a SURVEYOR assay according to the manufacturer's instructions.
For Small Genomic Modifications
This can be performed directly on the (unpurified) PCR product.
• If a restriction enzyme recognition site has been inserted or removed, perform restriction enzyme digestion of the PCR product.
• To verify mutations, clone the PCR products using the TOPO TA Cloning kit and sequence according to the manufacturer's instructions. 
DISCUSSION
Based on the targeting experiments we have performed (more than 400 different microinjections producing more than 100 new mouse strains), the great majority of microinjections with only Cas9 mRNA and sgRNAs resulted in mutant alleles containing indels with high efficiency (>80% of pups were targeted for one allele). The efficiency of targeted chromosomal deletions greatly depends on the size of the deletion; we have successfully deleted chromosomal regions up to~200 kb and have observed efficiencies for targeted deletions that range from 10% to 40% of born pups being targeted. With co-injection of donor ssDNA, the efficiency of HDR varies from 10% to 60% depending on the size of the fragment that is being inserted/modified. Using double-stranded plasmid donor DNA, the efficiency of HR varies greatly and requires significant optimization.
RELATED INFORMATION
A more detailed discussion on the background and uses of these techniques is available in Introduction: Editing the Mouse Genome Using the CRISPR-Cas9 System (Williams et al. 2016) . 
RECIPES
